跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,505 条关于
“Adlai Nortye Biopharma”
全部
2,505
临床试验
308
药物
427
机构
319
资讯
1,451
去年
Esophageal Cancer Pipeline Shows Promise with 100+ Therapies in Development Across 80+ Companies
去年
Adlai Nortye's AN2025 Shows Promise in Head and Neck Cancer Treatment
去年
Adlai Nortye to Showcase Novel Cancer Immunotherapy and RAS Inhibitor at AACR 2025
8个月前
Adlai Nortye Partners with ASK Pharm in $230 Million Deal for Pan-RAS Inhibitor AN9025 in Greater China
去年
Adlai Nortye's Buparlisib Poised to Potentially Be First PI3K Inhibitor for Head and Neck Cancer
2个月前
Adlai Nortye Advances First-in-Class Pan-RAS(ON) ADC AN4035 into Phase I Trial for RAS-Addicted Solid Tumors
2年前
Immix Biopharma's NXC-201 Shows Promise as Outpatient CAR-T Therapy in Amyloidosis and Multiple Myeloma
3个月前
India Launches Biopharma SHAKTI Initiative, Targets 100 Biologics by 2047 to Become Global Biopharma Hub
2年前
Kaida BioPharma Advances Novel Therapies for Gynecological Cancers, Launches Social Media Channels
25天前
Genetic Analysis Accelerates Clinical Development in Biopharma
第 1 页,共 146 页
上一页
下一页